Health Condition 1: N186- End stage renal disease
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Department of Pharmacology
Eligibility
Inclusion criteria
Inclusion criteria: Adult stable renal transplantation studies and patients with normal albumin range.
Exclusion criteria
Exclusion criteria: Patients with multi organ transplantation Pregnant or lactating women Patients with secondary infection or malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anticipated outcomes involve confirming the specificity and selectivity of the established High Performance Liquid Chromatography- fluorescence method for determining Mycophenolic Acid (MPA) concentrations in both saliva and plasma. The success of this method could position it as a reliable approach for Therapeutic Drug Monitoring (TDM) of MPA in diverse patient groups, irrespective of age.Timepoint: Before drug administration, 20 mins after drug administration followed at 1hr, 2hr, 4 hr , 6 hr , 8 hr and 12 hr | — |
Secondary
| Measure | Time frame |
|---|---|
| correlation between plasma AUC and saliva AUC of MPA in Renal transplant patientsTimepoint: Before drug administration, 20 mins after drug administration followed at 1hr, 2hr, 4 hr , 6 hr , 8 hr and 12 hr | — |
Countries
India
Contacts
Public ContactProf Smita Pattanaik
PGIMER
Outcome results
None listed